Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZB004 SAD in Healthy Volunteers
NCT05794516Phase 1Completed
- Sponsor
- Zenas BioPharma
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease comparing ZB004 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Jun 2023; status: completed.
02
Drugs
ZB004
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT05794516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794516.